91,084 Shares in OptiNose, Inc. (NASDAQ:OPTN) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in OptiNose, Inc. (NASDAQ:OPTN) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 91,084 shares of the company’s stock, valued at approximately $61,000.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in OptiNose by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock worth $6,194,000 after acquiring an additional 62,906 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of OptiNose by 2.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after purchasing an additional 81,233 shares during the period. XTX Topco Ltd acquired a new position in shares of OptiNose during the second quarter valued at about $88,000. Squarepoint Ops LLC grew its stake in shares of OptiNose by 173.7% in the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock valued at $178,000 after buying an additional 108,903 shares during the period. Finally, Easterly Investment Partners LLC grew its stake in shares of OptiNose by 5.0% in the 3rd quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock valued at $1,581,000 after buying an additional 113,015 shares during the period. Institutional investors and hedge funds own 85.60% of the company’s stock.

OptiNose Price Performance

NASDAQ:OPTN opened at $0.53 on Tuesday. OptiNose, Inc. has a one year low of $0.32 and a one year high of $2.10. The company has a market cap of $79.88 million, a PE ratio of -1.89 and a beta of -0.07. The firm has a 50-day moving average of $0.68 and a 200-day moving average of $0.93.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on OPTN. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of OptiNose in a research note on Wednesday, November 13th. Piper Sandler cut their target price on OptiNose from $3.00 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.